Chicago, ILNCT07284433Now EnrollingIRB Ready

Lymphoma Diffuse Large B-cell Clinical Trial in Chicago, IL

Access cutting-edge lymphoma diffuse large b-cell treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by AvenCell Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access lymphoma diffuse large b-cell specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related lymphoma diffuse large b-cell treatment provided free

Apply for This Chicago Location

Check if you qualify for this lymphoma diffuse large b-cell clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Lymphoma Diffuse Large B-cell Study in Chicago

This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, which can save time and reduce costs. It targets two proteins, CD19 and CD20, to lower the chance of relapse and uses gene editing to make it safer. The trial has three parts: first to find a safe dose, then to confirm it, and finally to test how well it works in patients with diffuse large B-cell lymphoma (DLBCL). Patients will get one infusion after chemotherapy to prepare their body. The main goal is to check safety and see how many patients have a complete response by Week 13. About 160 patients will take part, and researchers will follow them for up to 15 years.

Sponsor: AvenCell Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Adults 18 years or older.
Diagnosed with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or chronic lymphocytic leukemia (CLL).
Must have received at least 2 prior lines of therapy.
ECOG performance status 0-1 (able to carry out daily activities).
Adequate organ function (heart, liver, kidneys).
HLA B/C match with donor cells.
No active uncontrolled infections.

Exclusion Criteria

Active CNS involvement (including PCNSL) in dose escalation cohorts; may be allowed in later cohorts with Sponsor approval.
Prior CAR-T within 3 months of screening, or ≥Grade 3 ICAHT from prior CAR-T.
Autologous stem cell transplant within 3 months.
Prior allogeneic stem cell transplant or solid organ transplant.
Prior therapy with dual CD19/CD20 CAR-T.
Severe hypersensitivity to trial agents or similar compounds.
History of GvHD or post-transplant lymphoproliferative disorder.
Presence of La/SS-B autoantibodies or related autoimmune diseases.
Other malignancy that may interfere with trial, except:
Curatively treated basal/squamous skin cancer or cervical carcinoma in situ
Low-grade, early-stage prostate cancer (Gleason ≤6, Stage 1-2) with no therapy needed
Adjuvant endocrine therapy for non-metastatic breast cancer (≥2 years)
Any other curatively treated malignancy in remission ≥2 years
Active viral infection within 1 week of screening, or serious bacterial/fungal infection.
Hemorrhagic cystitis.
Active neuro-autoimmune disease (e.g., MS, Guillain-Barré, ALS).
Active or residual HBV, HCV, or syphilis.
Active HIV. History of HIV may be eligible with Sponsor approval if:
Neurological disorders within 6 months (e.g., stroke, dementia, Parkinson's, cerebellar disease, CNS autoimmune disease).
Significant cardiac disease within 6 months (e.g., MI, stent, unstable angina).
Primary immunodeficiency or autoimmune disease requiring systemic treatment within 1 year (unless stable and Sponsor-approved).
Unresolved ≥Grade 2 non-hematologic toxicity from prior therapy (except neuropathy up to Grade 2).
Systemic immunosuppression within 28 days.
Last systemic lymphoma/CLL therapy (standard or investigational) within 28 days or 5 half-lives.
Major surgery within 14 days.
Local radiation within 28 days.
Live vaccination within 28 days.
Pregnant or breastfeeding.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07284433) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Lymphoma Diffuse Large B-cell Treatment Options in Chicago, IL

If you're searching for lymphoma diffuse large b-cell treatment options in Chicago, IL, this clinical trial (NCT07284433) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lymphoma diffuse large b-cell specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all lymphoma diffuse large b-cell clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Chicago, IL

See all lymphoma clinical trials recruiting in Chicago — not just this study.

Browse Lymphoma Trials in Chicago →

Browse More Trials by Condition

Lymphoma TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL